HIMS Stock Prediction 2025: After a 150% YTD rally, HIMS now trades around $60–65 (UPD: May 18). But with the Street’s average HIMS stock price target still at $37, the question is: has the stock run too far — or is there more upside ahead?
HIMS Stock Prediction 2025–2026: Wall Street Analyst Targets
According to MarketBeat, analyst opinions on HIMS are clearly split — but there’s a middle ground. Over the past 12 months, 13 Wall Street analysts have issued ratings: 8 say “Hold,” 3 recommend buying, and 2 suggest selling the stock.
As for the price target, the average 12-month forecast is around $37. The most bullish call goes as high as $68 per share, while the most conservative sees it at just $23.
For context, HIMS shares were trading between $60 and $65 at the time of this update (May 18, 2025).
Why Is HIMS Stock Up? (April-May 2025)
In our blog, we’ve highlighted a few key reasons behind the rally. Here’s the quick version from GrowInvest:
1. Partnership with Novo Nordisk
In late April, Hims & Hers announced a partnership with Novo Nordisk to officially distribute Wegovy through its platform. This allowed them to stay in the GLP-1 game after compounded versions were restricted.
2. Strong Q1 Earnings
Wall Street didn’t see it coming. We break down the numbers a bit more below – they’re worth a closer look.
3. Leadership Hires from Amazon and AI
The company leveled up its executive team, bringing in a former Amazon leader and a new CTO with strong AI credentials. The market took notice.
4. $870 Million Convertible Notes Offering
In May, HIMS raised $870 million through convertible notes. The goal? Expansion, tech, and global reach. Ambitious? Absolutely – and investors liked it.
Why Is HIMS Stock Going Down? (February-March 2025)
However, just a few months earlier, the picture looked very different. February and March 2025 brought the early stages of Donald Trump’s new trade war – but that wasn’t the only issue:
1. FDA Ends the Semaglutide Shortage
On February 21, 2025, the FDA officially declared the semaglutide shortage over. For context, semaglutide is the active ingredient in Wegovy and Ozempic from Novo Nordisk.
While the drug was considered in shortage, Hims & Hers was allowed to sell compounded versions – basically custom-made alternatives – legally under U.S. pharmacy laws. But once the shortage ended, that revenue stream came under serious threat.
The market didn’t take it lightly: shares dropped nearly 40% as investors questioned the company’s business model.
2. Novo Nordisk Launches Its Own Pharmacy
On March 5, 2025, Novo Nordisk launched NovoCare Pharmacy – an FDA-approved service offering Wegovy at a lower price, with home delivery. That added even more pressure on Hims & Hers, both from a pricing and convenience standpoint.
HIMS Q1 2025 Earnings: Key Metrics
On May 5, 2025, Hims & Hers released strong financial results for Q1. The key metrics are summarized below:
- Revenue: $586 million (+111% YoY)
- Net Income: $49.5 million (up from $11.1 million YoY)
- Earnings Per Share (EPS): $0.20
- Subscribers: 2.4 million (+38% YoY)
- Average Revenue Per User (ARPU): $84 (+53% YoY)
- Free Cash Flow: $50.1 million
HIMS Earnings Date 2025: When Is the Next Report?
Hims & Hers Health is expected to report its Q2 2025 earnings on August 4, 2025. The date is based on the company’s historical reporting schedule.
HIMS Stock Prediction 2025: Growth Potential
We’ve also put together a list of potential growth drivers for Hims & Hers Health. We’re not repeating the Novo Nordisk partnership here — we covered that earlier. But there are still several areas worth keeping an eye on:
1. Expansion into New Health Categories
Starting in Q3 2025, Hims plans to launch new verticals like menopause support, low testosterone treatment, and longevity-focused care. Sleep and wellness may follow.
2. Investment in AI and Personalized Medicine
The company is betting big on AI and data-driven care – including personalized treatment plans and smarter patient support.
3. Global Expansion and Strategic Acquisitions
Hims has announced plans to expand internationally, both organically and via acquisitions. One example: buying Trybe Labs to bring at-home diagnostics into the ecosystem.
HIMS Stock Prediction 2025: Potential Risks & Challenges
Of course, there are risks – maybe not as obvious, but worth keeping in mind. We won’t rehash the FDA regulation issue (we already covered that above), but here are a few more factors investors should watch:
1. Political and Regulatory Uncertainty
Shifts in the U.S. political climate or changes in healthcare policy could impact Hims’ business model – especially in areas like hormone therapy and other sensitive treatments.
2. Volatility of HIMS Stock
Let’s be real – the stock isn’t for the faint of heart. HIMS is highly volatile, and price swings are part of the deal.
Example? Between February 13 and February 20, 2025, the stock traded between $60-68. Just one month later, in March, it was down around $30–35.
HIMS Stock Prediction 2025: Is HIMS a Good Stock to Buy in June 2025?
In my view, jumping into HIMS at $60–65 right now isn’t the best idea — especially with such modest analyst targets on the table. That said, as mentioned above, the company does have real potential.
For context: I first bought HIMS shares at $33.99 on March 7, 2025. As of today (May 18, 2025), I’m still holding — up a solid 80%. For now, I’ve decided to stay in.
If you found this piece helpful, we also recommend checking out our updated article on Reddit Stock Price Prediction 2025.
This article is for informational purposes only and does not constitute financial advice. The content reflects the author’s opinion and should not be interpreted as an investment recommendation.
FAQ: HIMS Stock Prediction 2025
What is the HIMS stock prediction for 2025?
Wall Street analysts are split: the average 12-month price target is $37, with high estimates at $68 and low ones at $23. As of May 18, 2025, the stock trades around $60–65.
What is the HIMS stock forecast for 2025–2026?
Analysts see mixed potential. 8 out of 13 recommend holding the stock, while 3 suggest buying and 2 recommend selling. Volatility remains a key concern.
What is the HIMS stock price target right now?
The current average price target from Wall Street analysts is $37. Some bullish targets go up to $68, while conservative ones sit at $23.
When is the HIMS earnings date for 2025?
Hims & Hers is expected to report Q2 2025 earnings on August 4, 2025, after market close. The date is based on their historical schedule.
Why is HIMS stock going down?
In February-March 2025, the FDA ended the semaglutide shortage and Novo Nordisk launched its own pharmacy – both events hit HIMS hard. Shares dropped nearly 40%.
Why did HIMS stock go up in April–May 2025?
Key drivers included strong Q1 earnings, a partnership with Novo Nordisk, leadership hires from Amazon and AI, and a $870M convertible notes offering.
Is HIMS a good stock to buy in June 2025?
At $60–65, the stock looks stretched relative to its $37 target. The company has potential, but personally, I’m holding after buying at $33.99 in March.
